Published in Chem Soc Rev on December 04, 2013
Volatile Markers in Digestive Cancer (VOLGACORE) | NCT02332213
Breathprints of model murine bacterial lung infections are linked with immune response. Eur Respir J (2014) 1.43
Technologies for Clinical Diagnosis Using Expired Human Breath Analysis. Diagnostics (Basel) (2015) 1.09
Advances in electronic-nose technologies for the detection of volatile biomarker metabolites in the human breath. Metabolites (2015) 1.03
Preparation and Gas Sensing Properties of In2O3/Au Nanorods for Detection of Volatile Organic Compounds in Exhaled Breath. Sci Rep (2015) 1.00
Analysis of exhaled breath for diagnosing head and neck squamous cell carcinoma: a feasibility study. Br J Cancer (2014) 0.94
Assessment of the exhalation kinetics of volatile cancer biomarkers based on their physicochemical properties. J Breath Res (2014) 0.90
The lung cancer breath signature: a comparative analysis of exhaled breath and air sampled from inside the lungs. Sci Rep (2015) 0.87
Combined volatolomics for monitoring of human body chemistry. Sci Rep (2014) 0.87
Breath analysis as a potential and non-invasive frontier in disease diagnosis: an overview. Metabolites (2015) 0.87
Detection of cancer through exhaled breath: a systematic review. Oncotarget (2015) 0.84
Novel multiarm polyethylene glycol-dihydroartemisinin conjugates enhancing therapeutic efficacy in non-small-cell lung cancer. Sci Rep (2014) 0.83
Unique volatolomic signatures of TP53 and KRAS in lung cells. Br J Cancer (2014) 0.82
Chemical analysis of whale breath volatiles: a case study for non-invasive field health diagnostics of marine mammals. Metabolites (2014) 0.79
Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. ACS Nano (2016) 0.78
Smelling the Diagnosis: The Electronic Nose as Diagnostic Tool in Inflammatory Arthritis. A Case-Reference Study. PLoS One (2016) 0.78
Exhaled breath analysis for the early detection of lung cancer: recent developments and future prospects. Lung Cancer (Auckl) (2017) 0.77
Differentiation between genetic mutations of breast cancer by breath volatolomics. Oncotarget (2015) 0.76
Quantitative analysis of volatile organic compounds released and consumed by rat L6 skeletal muscle cells in vitro. J Breath Res (2014) 0.76
Progress in the development of volatile exhaled breath signatures of lung cancer. Ann Am Thorac Soc (2015) 0.76
Gas-phase broadband spectroscopy using active sources: progress, status, and applications. J Opt Soc Am B (2016) 0.75
Product ion distributions for the reactions of NO(+) with some physiologically significant volatile organosulfur and organoselenium compounds obtained using a selective reagent ionization time-of-flight mass spectrometer. Rapid Commun Mass Spectrom (2014) 0.75
A Compendium of Volatile Organic Compounds (VOCs) Released By Human Cell Lines. Curr Med Chem (2016) 0.75
Product ion distributions for the reactions of NO(+) with some physiologically significant aldehydes obtained using a SRI-TOF-MS instrument. Int J Mass Spectrom (2014) 0.75
Piezoresistive Membrane Surface Stress Sensors for Characterization of Breath Samples of Head and Neck Cancer Patients. Sensors (Basel) (2016) 0.75
Prediction of blood:air and fat:air partition coefficients of volatile organic compounds for the interpretation of data in breath gas analysis. J Breath Res (2016) 0.75
Core-shell nanostructured hybrid composites for volatile organic compound detection. Int J Nanomedicine (2015) 0.75
Improvement of Toluene-Sensing Performance of SnO₂ Nanofibers by Pt Functionalization. Sensors (Basel) (2016) 0.75
Limonene in exhaled breath is elevated in hepatic encephalopathy. J Breath Res (2016) 0.75
The fluid mosaic model of the structure of cell membranes. Science (1972) 37.43
Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 20.60
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Lung cancer. N Engl J Med (2008) 13.49
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48
A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med (2007) 10.47
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev (2009) 6.46
The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science (2010) 6.38
MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell (2008) 5.34
Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A (2008) 5.08
p53 and metabolism. Nat Rev Cancer (2009) 5.05
Electronic nose: current status and future trends. Chem Rev (2008) 4.97
Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med (1992) 4.82
Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet (1999) 3.70
Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol (2008) 3.37
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst (2007) 3.25
Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol (2009) 3.16
Detection of lung cancer with volatile markers in the breath. Chest (2003) 3.09
Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med (2005) 2.94
Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med (1996) 2.85
Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors. Biosens Bioelectron (2003) 2.72
Breast cancer diagnosis and screening. Am Fam Physician (2000) 2.63
4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 2.38
Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer (2010) 2.35
Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol (1991) 2.35
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol (2008) 2.29
Lung cancer epigenetics and genetics. Int J Cancer (2008) 2.08
Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer (2009) 1.99
ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer (2007) 1.93
Variation in volatile organic compounds in the breath of normal humans. J Chromatogr B Biomed Sci Appl (1999) 1.91
An investigation on electronic nose diagnosis of lung cancer. Lung Cancer (2009) 1.85
Volatile organic compounds in exhaled air from patients with lung cancer. Clin Chem (1985) 1.83
Colorimetric sensor arrays for volatile organic compounds. Anal Chem (2006) 1.83
Volatile markers of breast cancer in the breath. Breast J (2003) 1.82
Partition coefficients of some aromatic hydrocarbons and ketones in water, blood and oil. Br J Ind Med (1979) 1.80
Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease. FASEB J (2007) 1.77
Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol (2009) 1.74
Diagnosis of head-and-neck cancer from exhaled breath. Br J Cancer (2011) 1.70
Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res (2005) 1.68
Electronic noses and disease diagnostics. Nat Rev Microbiol (2004) 1.61
Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark (2007) 1.60
Comparisons between mammalian and artificial olfaction based on arrays of carbon black-polymer composite vapor detectors. Acc Chem Res (2004) 1.57
Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol (2004) 1.57
Human exhaled air analytics: biomarkers of diseases. Biomed Chromatogr (2007) 1.56
Biologic monitoring of exposure to environmental chemicals throughout the life stages: requirements and issues for consideration for the National Children's Study. Environ Health Perspect (2005) 1.54
Volatile organic compounds of lung cancer and possible biochemical pathways. Chem Rev (2012) 1.54
Recent progress in carbon nanotube-based gas sensors. Nanotechnology (2008) 1.53
Determining concentration patterns of volatile compounds in exhaled breath by PTR-MS. J Breath Res (2009) 1.51
Mitochondria in cancer. Oncogene (2006) 1.50
The potential of the hydrocarbon breath test as a measure of lipid peroxidation. Free Radic Biol Med (1994) 1.48
TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells in vitro. Cancer Epidemiol Biomarkers Prev (2010) 1.46
Empirical relations predicting human and rat tissue:air partition coefficients of volatile organic compounds. Toxicol Appl Pharmacol (2000) 1.46
Isoprene and acetone concentration profiles during exercise on an ergometer. J Breath Res (2009) 1.43
An optoelectronic nose: "seeing" smells by means of colorimetric sensor arrays. MRS Bull (2004) 1.43
Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 in vitro. Cancer Cell Int (2008) 1.40
Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol (2007) 1.40
GC-MS analysis of breath odor compounds in liver patients. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.40
Detection of human metabolites using multi-capillary columns coupled to ion mobility spectrometers. J Chromatogr A (2005) 1.39
Breath gas aldehydes as biomarkers of lung cancer. Int J Cancer (2010) 1.38
The scent of disease: volatile organic compounds of the human body related to disease and disorder. J Biochem (2011) 1.36
A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr (1992) 1.35
Determination and prediction of tissue-gas partition coefficients. Int Arch Occup Environ Health (1986) 1.34
Are we finally winning the war on cancer? J Econ Perspect (2008) 1.33
Sniffing the unique "odor print" of non-small-cell lung cancer with gold nanoparticles. Small (2009) 1.33
Partition coefficients of some industrial aliphatic hydrocarbons (C5-C7) in blood and human tissues. Br J Ind Med (1985) 1.32
Exhaled biomarkers in lung cancer. Eur Respir J (2009) 1.31
A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst (2007) 1.30
Physiological modeling of isoprene dynamics in exhaled breath. J Theor Biol (2010) 1.29
Analysis of lung air from patients with bronchogenic carcinoma and controls using gas chromatography-mass spectrometry. J Chromatogr (1988) 1.28
Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree? Curr Opin Genet Dev (2010) 1.26
Prediction of breast cancer using volatile biomarkers in the breath. Breast Cancer Res Treat (2006) 1.26
Dynamic profiles of volatile organic compounds in exhaled breath as determined by a coupled PTR-MS/GC-MS study. Physiol Meas (2010) 1.26
Lung cancer biomarkers in exhaled breath. Expert Rev Mol Diagn (2011) 1.25
Oxidants and antioxidants in breast cancer. Antioxid Redox Signal (2000) 1.24
Sensors for breath testing: from nanomaterials to comprehensive disease detection. Acc Chem Res (2013) 1.24
Epigenetic control of gene expression in the lung. Am J Respir Crit Care Med (2011) 1.24
A computerized classification technique for screening for the presence of breath biomarkers in lung cancer. Clin Chem (1988) 1.23
Volatile biomarkers in the breath of women with breast cancer. J Breath Res (2010) 1.23
The electronic nose in respiratory medicine. Respiration (2012) 1.23
Quantitative breath analysis of volatile organic compounds of lung cancer patients. Lung Cancer (2009) 1.21
Measurement of endogenous acetone and isoprene in exhaled breath during sleep. Physiol Meas (2012) 1.21
Detection of lung cancer using weighted digital analysis of breath biomarkers. Clin Chim Acta (2008) 1.21
A breath test for malignant mesothelioma using an electronic nose. Eur Respir J (2011) 1.21
Investigation of volatile biomarkers in lung cancer blood using solid-phase microextraction and capillary gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.20
Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer. J Thorac Oncol (2012) 1.19
Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro. Anticancer Res (2009) 1.18
The versatile use of exhaled volatile organic compounds in human health and disease. J Breath Res (2012) 1.17
Investigation of volatile biomarkers in liver cancer blood using solid-phase microextraction and gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom (2008) 1.16
Classification of lung cancer histology by gold nanoparticle sensors. Nanomedicine (2011) 1.16
Breath isoprene--aspects of normal physiology related to age, gender and cholesterol profile as determined in a proton transfer reaction mass spectrometry study. Clin Chem Lab Med (2008) 1.15
A mathematical model for breath gas analysis of volatile organic compounds with special emphasis on acetone. J Math Biol (2011) 1.15
Detection of nonpolar molecules by means of carrier scattering in random networks of carbon nanotubes: toward diagnosis of diseases via breath samples. Nano Lett (2009) 1.15
14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J Clin Oncol (2005) 1.14
Nanomaterial-based sensors for detection of disease by volatile organic compounds. Nanomedicine (Lond) (2013) 1.14
Effect of humidity on nanoparticle-based chemiresistors: a comparison between synthetic and real-world samples. ACS Appl Mater Interfaces (2011) 1.13
Biomarkers in cancer screening, research and detection: present and future: a review. Biomarkers (2006) 1.12
Molecular analysis of volatile metabolites released specifically by Staphylococcus aureus and Pseudomonas aeruginosa. BMC Microbiol (2012) 1.11
Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time? J Natl Compr Canc Netw (2010) 1.11
Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol (2009) 3.16
Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer (2009) 1.99
Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry. Clin Chem Lab Med (2009) 1.64
Human exhaled air analytics: biomarkers of diseases. Biomed Chromatogr (2007) 1.56
Strong corruption of electrocardiograms caused by cardiopulmonary resuscitation reduces efficiency of two-channel methods for removing motion artefacts in non-shockable rhythms. Resuscitation (2009) 1.54
Volatile organic compounds of lung cancer and possible biochemical pathways. Chem Rev (2012) 1.54
TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells in vitro. Cancer Epidemiol Biomarkers Prev (2010) 1.46
Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 in vitro. Cancer Cell Int (2008) 1.40
Altered electrical activity of fibrillation process following thrombolytic therapy in out-of-hospital cardiac arrest patients with sustained ventricular fibrillation. Med Hypotheses (2006) 1.37
Vibrio cholerae strain typing and phylogeny study based on simple sequence repeats. J Clin Microbiol (2006) 1.29
Physiological modeling of isoprene dynamics in exhaled breath. J Theor Biol (2010) 1.29
Measurement of endogenous acetone and isoprene in exhaled breath during sleep. Physiol Meas (2012) 1.21
Implementation and interpretation of hydrogen breath tests. J Breath Res (2008) 1.21
Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro. Anticancer Res (2009) 1.18
Suitability of different polymer bags for storage of volatile sulphur compounds relevant to breath analysis. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.15
Breath isoprene--aspects of normal physiology related to age, gender and cholesterol profile as determined in a proton transfer reaction mass spectrometry study. Clin Chem Lab Med (2008) 1.15
A mathematical model for breath gas analysis of volatile organic compounds with special emphasis on acetone. J Math Biol (2011) 1.15
Molecular analysis of volatile metabolites released specifically by Staphylococcus aureus and Pseudomonas aeruginosa. BMC Microbiol (2012) 1.11
Breath biomarkers for lung cancer detection and assessment of smoking related effects--confounding variables, influence of normalization and statistical algorithms. Clin Chim Acta (2010) 1.07
Comparison of the dissolution of metaxalone tablets (Skelaxin) using USP Apparatus 2 and 3. AAPS PharmSciTech (2004) 1.07
Temporal profiling of human urine VOCs and its potential role under the ruins of collapsed buildings. Toxicol Mech Methods (2012) 1.04
Analysis of exhaled breath from smokers, passive smokers and non-smokers by solid-phase microextraction gas chromatography/mass spectrometry. Biomed Chromatogr (2009) 1.03
Blood and breath levels of selected volatile organic compounds in healthy volunteers. Analyst (2013) 1.02
Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells. Cancer Biomark (2010) 1.00
Ion mobility spectrometry for detection of skin volatiles. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.99
Removal of CPR artifacts from the ventricular fibrillation ECG by adaptive regression on lagged reference signals. IEEE Trans Biomed Eng (2008) 0.93
Volatile fingerprints of cancer specific genetic mutations. Nanomedicine (2013) 0.92
Breath acetone monitoring by portable Si:WO3 gas sensors. Anal Chim Acta (2012) 0.91
Characterization of volatile metabolites taken up by or released from Streptococcus pneumoniae and Haemophilus influenzae by using GC-MS. Microbiology (2012) 0.91
Compounds enhanced in a mass spectrometric profile of smokers' exhaled breath versus non-smokers as determined in a pilot study using PTR-MS. J Breath Res (2008) 0.90
Release and uptake of volatile organic compounds by human hepatocellular carcinoma cells (HepG2) in vitro. Cancer Cell Int (2013) 0.90
Assessment of the exhalation kinetics of volatile cancer biomarkers based on their physicochemical properties. J Breath Res (2014) 0.90
The effects of nifedipine on ventricular fibrillation mean frequency in a porcine model of prolonged cardiopulmonary resuscitation. Anesth Analg (2003) 0.90
Stability of selected volatile breath constituents in Tedlar, Kynar and Flexfilm sampling bags. Analyst (2013) 0.90
Optimization of sampling parameters for collection and preconcentration of alveolar air by needle traps. J Breath Res (2012) 0.89
Application of ion mobility spectrometry for the detection of human urine. Anal Bioanal Chem (2010) 0.87
Improved pre-concentration and detection methods for volatile sulphur breath constituents. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.87
Permeation profiles of potential urine-borne biomarkers of human presence over brick and concrete. Analyst (2012) 0.86
Measurement of isoprene solubility in water, human blood and plasma by multiple headspace extraction gas chromatography coupled with solid phase microextraction. J Breath Res (2011) 0.84
Preparation and characterization of microporous fibers for sample preparation and LC-MS determination of drugs. J Sep Sci (2009) 0.84
Comparative analyses of volatile organic compounds (VOCs) from patients, tumors and transformed cell lines for the validation of lung cancer-derived breath markers. J Breath Res (2014) 0.83
Temporally resolved fluctuation analysis of sleep ECG. J Biol Phys (2007) 0.83
Breath gas analysis for estimating physiological processes using anesthetic monitoring as a prototypic example. Conf Proc IEEE Eng Med Biol Soc (2011) 0.82
Breath analysis for in vivo detection of pathogens related to ventilator-associated pneumonia in intensive care patients: a prospective pilot study. J Breath Res (2015) 0.81
Human blood and plasma partition coefficients for C4-C8 n-alkanes, isoalkanes, and 1-alkenes. Int J Toxicol (2012) 0.81
Proton transfer reaction-mass spectrometry applications in medical research. J Breath Res (2009) 0.81
Near real-time VOCs analysis using an aspiration ion mobility spectrometer. J Breath Res (2013) 0.81
Geographical variation in the exhaled volatile organic compounds. J Breath Res (2013) 0.81
Simulation of interaction between two non-depolarizing muscle relaxants: generation of an additive or a supra-additive neuromuscular block. J Pharmacokinet Pharmacodyn (2004) 0.80
The role of methane in mammalian physiology-is it a gasotransmitter? J Breath Res (2015) 0.80
CPR artifact removal in ventricular fibrillation ECG signals using Gabor multipliers. IEEE Trans Biomed Eng (2009) 0.80
Monolayer-capped gold nanoparticles for disease detection from breath. Nanomedicine (Lond) (2014) 0.78
Detecting active pulmonary tuberculosis with a breath test using nanomaterial-based sensors. Eur Respir J (2014) 0.78
Modeling of twitch fade based on slow interaction of nondepolarizing muscle relaxants with the presynaptic receptors. J Pharmacokinet Pharmacodyn (2006) 0.78
Competition between acetylcholine and a nondepolarizing muscle relaxant for binding to the postsynaptic receptors at the motor end plate: simulation of twitch strength and neuromuscular block. J Pharmacokinet Pharmacodyn (2003) 0.78
Modeling-based determination of physiological parameters of systemic VOCs by breath gas analysis: a pilot study. J Breath Res (2015) 0.78
Determination of sevoflurane and its metabolite hexafluoroisopropanol by direct injection of human plasma into gas chromatography-tandem mass spectrometry. J Chromatogr A (2011) 0.78
Application of GC-MS with a SPME and thermal desorption technique for determination of dimethylamine and trimethylamine in gaseous samples for medical diagnostic purposes. J Breath Res (2010) 0.77
Multi-capillary-column proton-transfer-reaction time-of-flight mass spectrometry. J Chromatogr A (2013) 0.77
Diagnosing lactose malabsorption in children: difficulties in interpreting hydrogen breath test results. J Breath Res (2016) 0.77
Detection of potential chronic kidney disease markers in breath using gas chromatography with mass-spectral detection coupled with thermal desorption method. J Chromatogr A (2013) 0.76
Quantitative analysis of volatile organic compounds released and consumed by rat L6 skeletal muscle cells in vitro. J Breath Res (2014) 0.76
On the importance of developing a new generation of breath tests for Helicobacter pylori detection. J Breath Res (2015) 0.76
Detection of volatile malodorous compounds in breath: current analytical techniques and implications in human disease. Bioanalysis (2014) 0.76
Simulation of the reversal of neuromuscular block by sequestration of the free molecules of the muscle relaxant. J Pharmacokinet Pharmacodyn (2007) 0.76
Temperature-programmed gas chromatography linear retention indices of all C4-C30 monomethylalkanes on methylsilicone OV-1 stationary phase. Contribution towards a better understanding of volatile organic compounds in exhaled breath. J Chromatogr A (2007) 0.76
Analysis of volatile organic compounds liberated and metabolised by human umbilical vein endothelial cells (HUVEC) in vitro. Cell Biochem Biophys (2015) 0.75
Time to maximum effect site concentration. Anesthesiology (2004) 0.75
Modeling of breath methane concentration profiles during exercise on an ergometer. J Breath Res (2016) 0.75
Evaluation of septa quality for automatic SPME-GC-MS trace analysis. J Chromatogr Sci (2012) 0.75
Product ion distributions for the reactions of NO(+) with some physiologically significant volatile organosulfur and organoselenium compounds obtained using a selective reagent ionization time-of-flight mass spectrometer. Rapid Commun Mass Spectrom (2014) 0.75
A Compendium of Volatile Organic Compounds (VOCs) Released By Human Cell Lines. Curr Med Chem (2016) 0.75
Volume of the effect compartment in simulations of neuromuscular block. Theor Biol Med Model (2005) 0.75
ABA-Cloud: support for collaborative breath research. J Breath Res (2013) 0.75
Non-(13)CO2 targeted breath tests: a feasibility study. J Breath Res (2014) 0.75
Monitoring of selected skin-borne volatile markers of entrapped humans by selective reagent ionization time of flight mass spectrometry in NO+ mode. Anal Chem (2014) 0.75
First human exposure to Org 25969. Anesthesiology (2006) 0.75
The relationship between twitch depression and twitch fade during neuromuscular block produced by vecuronium: correlation with the release of acetylcholine. Theor Biol Med Model (2007) 0.75
Myasthenia gravis and myasthenic syndrome: simulation of twitch strength with or without therapy. Muscle Nerve (2005) 0.75
Equivalent chain lengths of all C4-C23 saturated monomethyl branched fatty acid methyl esters on methylsilicone OV-1 stationary phase. J Chromatogr A (2011) 0.75
Application of filtering methods for removal of resuscitation artifacts from human ECG signals. Conf Proc IEEE Eng Med Biol Soc (2008) 0.75
Physiologic-pharmacologic interpretation of the constants in the Hill equation for neuromuscular block: a hypothesis. J Pharmacokinet Pharmacodyn (2002) 0.75
Special section featuring selected articles from breath analysis 2014 (6-9 July 2014, Torun, Poland). J Breath Res (2015) 0.75
Environmental monitoring of Vibrio cholerae using chironomids in India. Environ Microbiol Rep (2009) 0.75
Breath 2009: International Conference on Breath and Breath Odor Research (26–30 April 2009, Dortmund, Germany). J Breath Res (2010) 0.75
Multiplexed Nanomaterial-Based Sensor Array for Detection of COVID-19 in Exhaled Breath. ACS Nano (2020) 0.75
Precursors for cytochrome P450 profiling breath tests from an in silico screening approach. J Breath Res (2014) 0.75